NCT01760993View on ClinicalTrials.gov

Long-term Safety of SPD489 When Added to Stable Doses of Antipsychotic Medications in Clinically Stable Adults With Negative Symptoms of Schizophrenia

PHASE3TerminatedINTERVENTIONAL
Enrollment

2

Participants

Timeline

Start Date

February 1, 2013

Primary Completion Date

April 1, 2013

Study Completion Date

April 1, 2013

Conditions
Schizophrenia
Interventions
DRUG

SPD489

Once-daily oral optimized doses of SPD489 (either 40 mg, 80 mg, 100 mg, 120 mg, 140 mg, or 160 mg) for 52 weeks

Trial Locations (2)

19139

CRI Lifetree, Philadelphia

73112

SP Research PLLC/Oklahoma Clinical Research Center, Oklahoma City

Sponsors

Lead Sponsor

Shire
All Listed Sponsors
lead

Shire

INDUSTRY

NCT01760993 - Long-term Safety of SPD489 When Added to Stable Doses of Antipsychotic Medications in Clinically Stable Adults With Negative Symptoms of Schizophrenia | Biotech Hunter | Biotech Hunter